#mindactivity

[pattytacuri]

poetry: strangers

I wrote this poem in June of 2023. bruh, you ruined it we could have been friends but you ruined itby crossing my boundariesby showing your unhealthy attachment to mesaying you’ll wait for me to change my mindacting like I’m a challenge to take onseeing me as an objection of your affection,a pretty girl to jack off toso I was left with no choice but to block youfrom my universeif you can’t…

[jcmarchi]

Researchers developing AI to make the internet more accessible - Technology Org

New Post has been published on https://thedigitalinsider.com/researchers-developing-ai-to-make-the-internet-more-accessible-technology-org/

Researchers developing AI to make the internet more accessible - Technology Org

In an effort to make the internet more accessible for people with disabilities, researchers at The Ohio State University have begun developing an artificial intelligence agent that could complete complex tasks on any website using simple language commands.  

An Apple computer – associative photo. Image credit: Dmitry Chernyshov via Unsplash, free license

The world wide web has become an intricate, dynamic system in the three decades since it was first released into the public domain. Yet because internet function is now so integral to society’s well-being, its complexity also makes it considerably harder to navigate.  

Today there are billions of websites available to help access information or communicate with others, and many tasks on the internet can take more than a dozen steps to complete. That’s why Yu Su, co-author of the study and an assistant professor of computer science and engineering at Ohio State, said their work, which uses information taken from live sites to create web agents — online AI helpers — is a step toward making the digital world a less confusing place.

“For some people, especially those with disabilities, it’s not easy for them to browse the internet,” said Su. “We rely more and more on the computing world in our daily life and work, but there are increasingly a lot of barriers to that access, which, to some degree, widens the disparity.” 

The study was presented in December at the Thirty-seventh Conference on Neural Information Processing Systems (NeurIPS), a flagship conference for AI and machine learning research. 

By taking advantage of the power of large language models, the agent works similarly to how humans behave when browsing the web, said Su. The Ohio State team showed that their model was able to understand the layout and functionality of different websites using only its ability to process and predict language.  

Researchers started the process by creating Mind2Web, the first dataset for generalist web agents. Though previous efforts to build web agents focused on toy simulated websites, Mind2Web fully embraces the complex and dynamic nature of real-world websites and emphasizes an agent’s ability of generalizing to entirely new websites it has never seen before. Su said that much of their success is due to their agent’s ability to handle the internet’s ever-evolving learning curve. The team lifted over 2,000 open-ended tasks from 137 different real-world websites, which they then used to train the agent.  

Some of the tasks included booking one-way and round-trip international flights, following celebrity accounts on Twitter, browsing comedy films from 1992 to 2017 streaming on Netflix, and even scheduling car knowledge tests at the DMV. Many of the tasks were very complex – for example, booking one of the international flights used in the model would take 14 actions. Such effortless versatility allows for diverse coverage on a number of websites, and opens up a new landscape for future models to explore and learn in an autonomous fashion, said Su.  

“It’s only become possible to do something like this because of the recent development of large language models like ChatGPT,” said Su. Since the chatbot became public in November 2022, millions of users have used it to automatically generate content, from poetry and jokes to cooking advice and medical diagnoses.  

Still, because one website could contain thousands of raw HTML elements, it would be too costly to feed so much information to a single large language model. To address this gap, the study also introduces a framework called MindAct, a two-pronged agent that uses both small and large language models to carry out these tasks. The team found that by using this strategy, MindAct significantly outperforms other common modeling strategies and is able to understand various concepts at a decent level. 

With more fine-tuning, the study points out, the model could likely be used in tandem with both open-and closed-source large language models such as Flan-T5 or GPT-4. However, their work does highlight an increasingly relevant ethical problem in creating flexible artificial intelligence, said Su. While it could certainly serve as a helpful agent to humans surfing the web, the model could also be used to enhance systems like ChatGPT and turn the entire internet into an unprecedentedly powerful tool, said Su.  

“On the one hand, we have great potential to improve our efficiency and to allow us to focus on the most creative part of our work,” he said. “But on the other hand, there’s tremendous potential for harm.” For instance, autonomous agents able to translate online steps into the real world could influence society by taking potentially dangerous actions, such as misusing financial information or spreading misinformation. 

“We should be extremely cautious about these factors and make a concerted effort to try to mitigate them,” said Su. But as AI research continues to evolve, he notes that it’s likely society will experience major growth in the commercial use and performance of generalist web agents in the years to come, especially as the technology has already gained so much popularity in the public eye.  

“Throughout my career, my goal has always been trying to bridge the gap between human users and the computing world,” said Su. “That said, the real value of this tool is that it will really save people time and make the impossible possible.” 

Source: Ohio State University

You can offer your link to a page which is relevant to the topic of this post.

[mary35miles-blog]

Kindly Register here for FREE Consultation from our #Advanced # #Consultant https://transformyourhealthutube.gr8.com/

[vimukti33]

#mindmagic #memory #improveyourskills #mindactivity https://www.instagram.com/p/B1YJCrdnDpU/?igshid=1pugdhya9z752

[rodprojects]

Always try to find time for travel at least little bit, for get as much inspiration as possible for the nest project. #coolstyle #manstyle #mymind ymindset #bestmindset #coolmindset #awesomwmindset #amazingmind #amazingguy #stylishman #roughguy #onlyroughlook #onlyharshlook #hardstyleman #hardstylelook #hardmodel #harshmodel #manmodel #maninblack #rickwrstyle #rockstyle #justrock #justrockstyle #rockman #rockguy #roughmanstyle #harshmanstyle #strongstyle #strongmanstyle #travelactivity #mindactivity (at Mumbai - मुंबई) https://www.instagram.com/p/CaZ85PtpcWu/?utm_medium=tumblr

[arrangoiz]

MINDACT Trial

The MINDACT: Is a randomized, controlled, prospective, phase III, clinical trial: Evaluating the use of a 70-gene signature test (MammaPrint): To aid in directing chemotherapy treatment of women with early-stage breast cancer The goal of this study was: To reduce the overtreatment of early-stage breast cancer To determine if genomic risk (as defined by the 70-gene signature test) can be…

[cnsessenceofdreams]

Real and Random

Still waiting on myselfThinking about nothingRinging in my earsOpening upNot seeing anything right with meGhosts all around inside of meHeightened sense of feelingAmazing thoughts of the futureProbably not how I dreamedProbably nowhere near the worstYet I’m going to make the best of itBright eyesExcited mindActs of kindnessUnder my own thumbTrying to appreciate myselfInkling of just the right…

[blackgoldgoddess]

Its all about habit. And the most pressing question you want to ask yourself is "are yours serving you?" Acknowledged as good or bad is irrelevant. B/c monkeys can be disciplined. #makewealthahabit #Habit #Wealthybeliefs #mindpower #moneymoves #moneypowerrespect #Mindaction

[drenriquevicentegreco]

New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. Open Access.

New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. Open Access.

Abstract:

This podcast presents an overview of new therapies on the horizon for breast cancer in terms of data presented at the European Society for Medical Oncology Congress, American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium.

In the adjuvant setting, results from the Microarray In Node negative Disease may Avoid ChemoTherapy (MINDACT) trial, which evaluated…

[oncologytube]

Adam Brufsky, MD on MINDACT and HER2 Guidelines in Genomic Profiling #ASCO2020

http://dlvr.it/Rc1bdn

[arrangoiz]

Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) Trial

Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) Trial

The MINDACT is a randomized, controlled, prospective, phase III, clinical trial:

Evaluating the use of a 70-gene signature test (MammaPrint):

To aid in directing chemotherapy treatment of women with early-stage breast cancer

The goal of this study:

Was to reduce the overtreatment of early-stage breast cancer and

To determine if genomic risk (as defined by the 70-gene signature test):

Can be utilized…

[azveille]

Cancer du sein : la HAS défavorable à la prise en charge des signatures génomiques

La Haute autorité de santé (HAS) ne recommande pas la prise en charge par la collectivité des signatures génomiques pour guider la prescription d'une chimiothérapie adjuvante dans le cancer du sein, dans un rapport mis en ligne lundi sur son site.

Ce rapport d'évaluation technologique concernait quatre signatures génomiques: les tests de première génération Oncotype DX* (Genomic Health) et MammaPrint* (Agendia) ainsi que deux de deuxième génération, Prosigna* (NanoString) et Endopredict* (Myriad). Ces tests sont actuellement financés de manière dérogatoire via leur inscription au référentiel des actes innovants hors nomenclature (RIHN).

Pour les cancers du sein infiltrants, les signatures génomiques permettent d'estimer un risque de récidive à partir de l'expression d'un panel de gènes dans la tumeur. Concernant les patientes pour lesquelles les critères clinico-pathologiques ne lèvent pas toutes les incertitudes, ces signatures "pourraient être un outil d'amélioration de la décision thérapeutique", écrit la HAS, dans un communiqué accompagnant le rapport d'évaluation.

L'agence pointe le fait que, "dans la très grande majorité des situations", les critères clinico-pathologiques identifient "clairement" les cancers à faible risque de récidive, pour lesquels la chimiothérapie adjuvante n'est pas utile, ainsi que les cancers à haut risque de récidive, pour lesquels elle est recommandée.

Selon la HAS, la signature ne présente donc un intérêt que chez les patientes à risque intermédiaire de récidive pour lesquelles il peut exister une incertitude décisionnelle. Le groupe de travail a défini cette population: les femmes dont la tumeur mesure entre 1 et 5 cm, qui est sensible à l'hormonothérapie adjuvante, HER2-, de grade 2, sans envahissement ganglionnaire ou avec un micro-envahissement. Cela représenterait 5% à 10% des femmes atteintes d'un cancer du sein infiltrant.

Pour la HAS, l'utilisation en dehors de cette population pourrait engendrer un risque de dissuader de recourir à une chimiothérapie des patientes qui en auraient besoin et inversement, un risque de "sur-traitement délétère" dans d'autres situations.

En outre, la HAS estime que les essais cliniques évaluant ces tests ne permettent pas de déterminer si, dans la population d'intérêt qu'elle décrit, les signatures présentent une valeur ajoutée par rapport aux critères clinico-pathologiques existants. La HAS souligne que les études portent principalement sur des populations qui ne correspondent pas à la population d'intérêt.

Quatre études ont été retenues par le groupe de travail : MINDACT (cf dépêche du 19/04/2016 à 12:07) , TAILORx (cf dépêche du 04/06/2018 à 15:58), PLAN B (cf dépêche du 03/03/2016 à 18:19) et résultats préliminaires d'OPTIMA. La population de patientes incluses dans ces essais était plus large que la population d'intérêt ciblée par la HAS.

Par ailleurs, l'agence souligne que, pour une même patiente, la décision de chimiothérapie adjuvante diffère dans 20% à 25 % des cas selon la signature génomique utilisée. "Ceci interroge sur la fiabilité respective des tests lors de leur utilisation auprès de la population d’intérêt et rend nécessaire des études comparatives", estime la HAS.

En outre, la HAS juge qu'il n'existe pas de preuve directes de l'utilité clinique des signatures génomiques de première génération en complément des critères clinico-pathologiques.

Pour ces raisons, la HAS considère que le service médical rendu par les quatre signatures génomiques est insuffisant.

La HAS préconise toutefois de maintenir le financement dérogatoire de ces dispositifs médicaux dans le cadre du RIHN, à la condition "sine qua non" de la réalisation d'une étude clinique prospective comparative permettant de recueillir exhaustivement des données cliniques pertinentes et exploitables.

Le rapport précise le design de l'essai.

Dans un communiqué diffusé lundi, la Société française de médecine prédictive et personnalisée estime que la conduite d'un tel essai est "vouée à l'échec" puisque les trois premières années d'utilisation en France n'ont pas permis de mettre en place un observatoire national pour mieux identifier la population cible. "Quand bien même ces études seraient menées, leur valeur scientifique serait bien plus faible que celle des études aujourd'hui disponibles", selon la société savante.

Elle pointe le fait que plusieurs pays de l'OCDE ont ouvert l'accès à ces tests et à leur prise en charge en suivant des recommandations nationales et internationales rédigées sur la base d'essais prospectifs et rétrospectifs confirmant la valeur pronostique de ces tests et leur utilité clinique.

La société savante rappelle que plusieurs grands centres français ont participé à ces études et fait valoir que la population traitée en France est dans la moyenne européenne.

[cancersfakianakis1]

MINDACT study results show low risk of local recurrence after 5 years for patients with early breast cancer

Cancer, Volume 124, Issue 17, Page 3466-3467, September 1, 2018. https://ift.tt/2OzDctj

[enzaime-blog]

Who Needs Chemotherapy after Treatment for Early Breast Cancer?

New Story has been published on https://enzaime.com/needs-chemotherapy-treatment-early-breast-cancer/

Who Needs Chemotherapy after Treatment for Early Breast Cancer?

Following surgery and/or radiation for early stage breast cancer, chemotherapy is sometimes given to eliminate remaining cancer cells that could cause trouble later. Traditionally, women have been more likely to undergo follow-up chemotherapy if clinical and pathological factors suggested a significant risk of recurrence, such as a larger tumor, higher stage and pathological grade of the cancer, or more lymph nodes containing cancer cells. In the past 10 years, genomic tests such as Oncotype DX and MammaPrint have brought a precision medicine approach to predicting recurrence risk; the tests look at a “signature” of gene activity to gauge the odds that remaining cancer cells will later spread through the body and threaten life. These genomic profile tests are performed on cancerous tissue collected during breast surgery, and look at a “signature” of gene activity. By monitoring the tissue’s genetic signature, the tests help estimate how much chemotherapy might lower the risk that cancer will return. Women who have low scores on these tests are considered at lower risk of recurrence, and the benefits of chemotherapy beyond that provided by pills that block or lower hormones (for cancers that are sensitive to the influences of hormones) may be minimal. But what about women who fall into a gray area? In some patients, clinical and pathological indicators point to a recurrence risk great enough to strongly consider chemotherapy. At the same time, genomic tests of the same women’s tumors may predict a low recurrence risk and no chemotherapy benefit, not worth subjecting the patient to the side effects of additional treatment. A large study published last August in the New England Journal of Medicine on this question recently found that women in this mixed group fared about the same whether or not they received chemotherapy. Even though their treated tumor may have had aggressive-looking features, if its genomic profile on the MammaPrint test was low-risk, the cancer was unlikely to spread – with or without chemotherapy. At five years, the survival rate of women without distant metastases was 94.7 percent among those who did not receive chemotherapy – just 1.5 percent lower than those women who received chemotherapy. “Given these findings, approximately 46 percent of women with breast cancer who are at high clinical risk might not require chemotherapy,” said the authors of the study, called MINDACT. “This study, among others, continues to show the importance of tumor genomics and biology when making decisions about treatment,” says Rachel Freedman, MD, MPH, a breast oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber. LEARN MORE: Breast Cancer: When is Less Treatment Better? How Much Radiation Do Breast Cancer Patients Need? Drinking in Early Adulthood Can Increase Breast Cancer Risk The study involved 6,693 women ages 18 to 70 at 112 institutions in nine European countries. They had primary invasive breast cancer, stage TI or TII or operable TIII, and up to three positive lymph nodes under the arm. “Deciding whether or not chemotherapy should be a part of a patient’s treatment plan is an individualized discussion based on the anticipated risk for recurrence, expected benefits of treatment, competing risks from other medical conditions, and personal preferences,” notes Freedman. “Traditionally, we had only the clinical features of a cancer to inform treatment recommendations, but now we increasingly incorporate the biology and/or genetic features of a cancer as well,” she continues. “This improved understanding of who is and isn’t expected to benefit from chemotherapy has spared many women from receiving this treatment unnecessarily. This study adds to the growing body of evidence that a substantial number of women with breast cancer will not need to receive chemotherapy to do well.”

[pageinextremis]

In future, it is possible that up to 46% of patients who would have received chemotherapy in the past could be spared from this treatment and its side effects.

The first results of the MINDACT trial give hope to many women with early-stage breast cancer.

Discover in the last BIG annual report, the success story of an academic trial that has the potential to change the future of breast cancer treatment.

BIG is an international non-profit organisation for academic breast cancer research groups from around the world. The association is the most extensive global research network dedicated solely to breast cancer. BIG encompasses 55 member groups worldwide, which are breast cancer focused collaborative research groups or data centres.

Global collaboration is crucial to make significant advances in breast cancer research, reducing unnecessary duplication of effort, sharing data and enabling collaboration of scientists across borders, contributing to the faster development of better treatments, and increasing the likelihood of cures for patients.

Page in extremis is happy to participate in the creative development and the graphical production of the BIG’s annual report. The result is a vibrant publication made within an intimate inventive dialogue framework involving the Belgian communication agency’s creative team and the BIG’s communication team.

Page in extremis is specialised in communication with sensitive issues. The communication agency creates and refreshes human-centred brands and develops percussive digital and classic media.

The communication agency has defined a very accurate process including monitoring and quality check particularly suited to provide maximum comfort to its clients and the best results.

Each year, the team of Page in extremis signs the design and produces about twenty annual reports.

Since 1994, the broad experience of the communication agency has been extended to more than four hundred annual reports.

Be surprised by our know-how, contact us!

More information: http://www.inextremis.be

[frapedoypoli]

Οι επιστήμονες βρήκαν ότι σχεδόν ένας στους τέσσερις μικρούς όγκους είναι επιθετικός και οι ασθενείς μπορούν να ωφεληθούν από την...

έγκαιρη χημειοθεραπεία, σύμφωνα με το ΑΠΕ. Οι επιθετικοί όγκοι μπορούν να ανιχνευθούν από την «υπογραφή» 70 γονιδίων.

«Τα ευρήματά μας αμφισβητούν την υπόθεση ότι όλοι οι μικροί όγκοι είναι λιγότερο σοβαροί και δεν χρειάζονται χημειοθεραπεία», δήλωσε ο επικεφαλής της έρευνας δρ Κωνσταντίνος Τρυφωνίδης, ογκολόγος, ερευνητής του Ευρωπαϊκού Οργανισμού για την Έρευνα και Θεραπεία του Καρκίνου (EORTC) στις Βρυξέλλες.

 Η μελέτη, με την ονομασία MINDACT, που παρουσιάσθηκε στο συνέδριο της Ευρωπαϊκής Εταιρείας Ιατρικής Ογκολογίας (ESMO 2017) στη Μαδρίτη, πραγματοποιήθηκε σε σχεδόν 6.700 γυναίκες με αρχικού σταδίου καρκίνο του μαστού. Οι 826 ασθενείς είχαν όγκο μεγέθους μικρότερου του ενός εκατοστού και, από αυτές, το 24% -παρόλο που δεν είχαν καρκίνο στους λεμφαδένες τους- είχαν επιθετική βιολογία και βρέθηκαν να έχουν μικρούς όγκους με κίνδυνο μακρινών μεταστάσεων στο σώμα.

vita.gr

Πηγή: http://ift.tt/2f1eFJQ http://ift.tt/2gAXZIV